Literature DB >> 24104188

Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells.

Garth W Tormoen1, Olivia Recht, András Gruber, Ross L Levine, Owen J T McCarty.   

Abstract

Patients with acute myelogenous leukemia (AML) are at risk for thrombotic complications. Risk to develop thrombosis is closely tied to leukemia subtype, and studies have shown an association between leukocytosis and thrombosis in AML M3. We evaluated the relative roles of cell count and the surface expression of tissue factor (TF) and phosphatidylserine (PS) in the procoagulant phenotype of AML cell lines. The TF-positive AML M3 cell lines, NB4 and HL60, and AML M2 cell line, AML14, exhibited both extrinsic tenase and prothrombinase activity in a purified system and promoted experimental thrombus formation. In contrast, the TF-negative AML cell line, HEL, exhibited only prothrombinase activity and did not affect the rate of occlusive thrombus formation. In plasma, NB4, HL60 and AML14 shortened clotting times in a cell-count, PS- and TF-dependent manner. Exposure of cultured NB4, HL60, and AML14 cells to the chemotherapeutic agent daunorubicin increased their extrinsic tenase activity and PS expression. Clot initiation time inversely correlated with logarithm of PS index, defined as the product of multiplying leukocyte count with cell surface PS exposure. We propose that leukemia cell PS index may serve as a biomarker for procoagulant activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24104188      PMCID: PMC3875408          DOI: 10.1088/1478-3975/10/5/056010

Source DB:  PubMed          Journal:  Phys Biol        ISSN: 1478-3967            Impact factor:   2.583


  33 in total

1.  The local phospholipid environment modulates the activation of blood clotting.

Authors:  Andrew W Shaw; Vincent S Pureza; Stephen G Sligar; James H Morrissey
Journal:  J Biol Chem       Date:  2007-01-02       Impact factor: 5.157

Review 2.  Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies.

Authors:  C López-Pedrera; N Barbarroja; G Dorado; E Siendones; F Velasco
Journal:  Leukemia       Date:  2006-05-25       Impact factor: 11.528

3.  Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features.

Authors:  M Breccia; G Avvisati; R Latagliata; I Carmosino; A Guarini; M S De Propris; F Gentilini; M C Petti; G Cimino; F Mandelli; F Lo-Coco
Journal:  Leukemia       Date:  2006-08-24       Impact factor: 11.528

4.  Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.

Authors:  Sophie Ziegler; Wolfgang R Sperr; Paul Knöbl; Stephan Lehr; Ansgar Weltermann; Ulrich Jäger; Peter Valent; Klaus Lechner
Journal:  Thromb Res       Date:  2005       Impact factor: 3.944

5.  Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis.

Authors:  Lorella Melillo; Elvira Grandone; Donatella Colaizzo; Filomena Cappucci; Maria Rosa Valvano; Nicola Cascavilla
Journal:  Acta Haematol       Date:  2007-01-18       Impact factor: 2.195

6.  Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival.

Authors:  Grace H Ku; Richard H White; Helen K Chew; Danielle J Harvey; Hong Zhou; Ted Wun
Journal:  Blood       Date:  2008-12-16       Impact factor: 22.113

7.  Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.

Authors:  Anna Falanga; Frederick R Rickles
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

Review 8.  Venous thromboembolism in the hematologic malignancies.

Authors:  Anna Falanga; Marina Marchetti
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

9.  An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF.

Authors:  Florian Langer; Ali Amirkhosravi; Sonja Loges; Todd Meyer; Barbara Eifrig; Dieter K Hossfeld; Walter Fiedler; John L Francis
Journal:  Thromb Haemost       Date:  2004-11       Impact factor: 5.249

10.  Increased risk of venous thromboembolism in patients with acute leukaemia.

Authors:  M Mohren; I Markmann; K Jentsch-Ullrich; M Koenigsmann; G Lutze; A Franke
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  6 in total

1.  Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia.

Authors:  Damien Gheldof; Hélène Haguet; Jean-Michel Dogné; Céline Bouvy; Carlos Graux; Fabienne George; Anne Sonet; Christian Chatelain; Bernard Chatelain; François Mullier
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

2.  Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.

Authors:  Garth W Tormoen; Tiffany C Blair; Shelly Bambina; Gwen Kramer; Jason Baird; Ramtin Rahmani; John M Holland; Owen J T McCarty; Michael J Baine; Vivek Verma; Nima Nabavizadeh; Michael J Gough; Marka Crittenden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-18       Impact factor: 7.038

3.  The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation.

Authors:  Kevin G Phillips; Angela M Lee; Garth W Tormoen; Rachel A Rigg; Anand Kolatkar; Madelyn Luttgen; Kelly Bethel; Lyudmila Bazhenova; Peter Kuhn; Paul Newton; Owen J T McCarty
Journal:  Am J Physiol Cell Physiol       Date:  2014-11-19       Impact factor: 4.249

Review 4.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

5.  Prognostic implications and procoagulant activity of phosphatidylserine exposure of blood cells and microparticles in patients with atrial fibrillation treated with pulmonary vein isolation.

Authors:  Huan Meng; Junjie Kou; Ruishuang Ma; Wenbo Ding; Yan Kou; Muhua Cao; Zengxiang Dong; Yayan Bi; Hemant S Thatte; Jialan Shi
Journal:  Mol Med Rep       Date:  2017-10-11       Impact factor: 2.952

6.  Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.

Authors:  Sylvie Dunoyer-Geindre; Anne-Sophie Rivier-Cordey; Olga Tsopra; Thomas Lecompte; Egbert K O Kruithof
Journal:  Ann Hematol       Date:  2017-03-25       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.